
IDYA Stock Forecast & Price Target
IDYA Analyst Ratings
Bulls say
IDEAYA Biosciences is viewed favorably because its lead darovasertib program is now at a major inflection point, with the NDA submitted in 3Q26 under the RTOR program and clinical data supporting a potentially broad label across HLA-A2 positive and negative metastatic uveal melanoma. The company also has multiple late-stage shots on goal, including IDE849 with encouraging efficacy and survival signals in SCLC and NEC and planned 3Q trials, plus IDE892 and IDE397 advancing through MTAP-deleted and RAS-combination strategies that could unlock sizable long-term sales potential. Financially, IDEAYA ended 3Q26 with $1.15B in cash and equivalents and guided runway into 2030, while higher R&D and SG&A reflect deliberate investment in a pipeline that appears increasingly de-risked and commercially relevant.
Bears say
IDEAYA Biosciences is viewed as highly exposed to binary clinical outcomes, with the downside case hinging on darovasertib failing to gain approval in MUM or neo-adjuvant UM and on the company not establishing clear forward paths for its pipeline. Disappointing PFS data for daro, a challenged neo-adjuvant UM market, and possible efficacy or safety setbacks for IDE397 or IDE849 could severely impair the investment case, while commercialization remains uncertain. With multiple layers of clinical, regulatory, liquidity, competitive, and partnership risk, the shares could trade closer to cash at $10/share if these programs underperform.
This aggregate rating is based on analysts' research of Ideaya Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
IDYA Analyst Forecast & Price Prediction
Start investing in IDYA
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Ideaya Biosciences Inc (IDYA) Forecast
IDYA Analyst Forecast & Price Prediction
Start investing in IDYA
Order type
Buy in
Order amount
Est. shares
0 shares